media – Page 10 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

First Hexavalent Rotavirus Vaccine Completes First Dose Vaccination

Shanghai Securities News / China Securities Online (Reporter: Zhang Xue) — On December 26, the oral hexavalent rotavirus vaccine, independently developed by the Wuhan Institute of Biological Products under Sinopharm CNBG, completed its first dose vaccination. According to CNBG, this is the world’s first vaccine covering six rotavirus serotypes to officially enter the practical application stage. Rotavirus is a primary pathogen causing acute severe diarrhea in infants and young children, characterized by wide transmission and significant health risks. The oral hexavalent rotavirus vaccine administered in this first dose covers six major serotypes—G1, G2, G3, G4, G8, and G9—achieving full coverage of China’s currently dominant circulating G-type strains for the first time. Li Ruizhen, deputy chief physician of the Child Healthcare Department at Wuhan Children’s Hospital, pointed out that multivalent vaccines help expand the scope of immune protection and are of positive significance in reducing the occurrence of severe diarrhea and ...
- Source: drugdu
- 78
- December 31, 2025
Progress Made in Research on Treatment for Drug-Resistant Bacterial Meningitis

People’s Daily Online, Beijing, Dec. 30 (Reporter: Zhao Zhuaqing) — Bacterial meningitis poses a severe threat to human health. ESKAPE pathogens, a major cause of hospital-acquired infections, have been defined by the World Health Organization (WHO) as priority pathogens requiring critical or high-priority action. The blood-brain barrier (BBB) blocks nearly 100% of large molecules and 98% of small molecules from entering the brain, making the treatment of meningitis particularly difficult. While Host Defense Peptides (HDPs) and their mimetics are considered highly promising candidates against drug-resistant bacterial infections, their application in meningitis research has been hindered by weak broad-spectrum antibacterial activity or an inability to penetrate the BBB. The Suzhou Institute of Biomedical Engineering and Technology (SIBET) of the Chinese Academy of Sciences has proposed an innovative strategy: “using biguanide as a novel cationic side-chain group for HDP mimetics.” Leveraging the high charge density and strong phospholipid binding capacity of the ...
- Source: drugdu
- 72
- December 31, 2025
Fosun Pharma Commences Phase I Clinical Trial for Nuclear Medicine Project SRT-007

Beijing Business Today News (December 30): Fosun Pharma announced that its subsidiary, Chengdu Xingrui Jingxuan Biotechnology Co., Ltd., has initiated Phase I clinical trials in Mainland China (excluding Hong Kong, Macau, and Taiwan) for SRT-007, an integrated diagnostic and therapeutic (theranostic) nuclear medicine project. The indication is for the diagnosis and treatment of PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). According to the announcement, the theranostic project SRT-007 consists of two injections: Gallium [68Ga] PSMA-0057 (for diagnosis) and Lutetium [177Lu] PSMA-0057 (for treatment). Specifically, Gallium [68Ga] PSMA-0057 injection is a diagnostic radiopharmaceutical, while Lutetium [177Lu] PSMA-0057 injection is a therapeutic radiopharmaceutical. https://finance.eastmoney.com/a/202512303605807463.html
- Source: drugdu
- 65
- December 31, 2025
AmoyDx’s “Human BRCA1/BRCA2 Gene Mutation Detection Kit” Granted Approval

On December 30, AmoyDx (300685) announced that the company recently received the “Medical Device Registration Certificate of the People’s Republic of China” issued by the National Medical Products Administration (NMPA). The registration is valid from December 29, 2025, to December 28, 2030. The approved product is the “Human BRCA1/BRCA2 Gene Mutation Detection Kit (Reversible Terminator Sequencing),” a Class III medical device primarily used for the in vitro qualitative detection of gene mutations in prostate cancer patients. This kit marks the first domestic approval of a Homologous Recombination Deficiency (HRD) test for prostate cancer indications, offering comprehensive coverage of various mutation types. The product, along with its companion drug Niraparib and Abiraterone Acetate tablets, has been included in the National Reimbursement Drug List (NRDL). This integration creates a synergistic “Precision Testing + Medical Insurance Medication” system, which helps improve treatment accessibility for patients. In the first three quarters of 2025, AmoyDx ...
- Source: drugdu
- 66
- December 31, 2025
Received Clinical Trial Approval for a New Indication of Innovative Drug HSK44459 Tablets

Haisco announced on December 30 that the company has received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration (NMPA). The notice approves the commencement of clinical trials for HSK44459 tablets for the treatment of inflammatory bowel disease (including ulcerative colitis and Crohn’s disease). This drug was independently developed by the company with independent intellectual property rights. Pre-clinical studies indicate that it has a clear target, definite efficacy, and good safety, making it a promising effective treatment for inflammatory bowel disease. However, it should be noted that the research and development of innovative drugs involves long cycles, numerous stages, and high risks, and is subject to uncertainties. https://finance.eastmoney.com/a/202512303605708953.html
- Source: drugdu
- 65
- December 31, 2025
【EXPERT Q&A】What Do Class I, II, and III Medical Devices Specifically Refer to in the Classification of Medical Devices? What Are the Classification Bases?

Drugdu.com expert’s response: I. Specific Definitions of Class I, II, and III Medical Devices Class I Medical Devices Definition: Medical devices with a low degree of risk, whose safety and effectiveness can be guaranteed through routine management. Typical Products: Surgical knives, medical fever-reducing patches, stethoscopes, tongue depressors, medical magnifying glasses, surgical gowns, examination gloves, etc. Management Requirements: Subject to filing management. Production filing is the responsibility of municipal drug regulatory authorities, and no permit is required for operation. Class II Medical Devices Definition: Medical devices with a moderate degree of risk, requiring strict control and management to ensure their safety and effectiveness. Typical Products: Thermometers, blood pressure monitors, blood glucose meters, medical masks, electrocardiographs, B-ultrasound machines, condoms, etc. Management Requirements: Subject to provincial registration. Production requires a “Medical Device Production License,” and operation requires a “Medical Device Business License.” Class III Medical Devices Definition: Medical devices with a relatively high ...
- Source: drugdu
- 68
- December 31, 2025
Huihe Medical Completes Hundreds of Millions-yuan Series D Financing Round with China Taiping Healthcare Fund as Lead Investor, Fueling Chinese Indigenous Medical Devices for Global Expansion

Recently, Shanghai Huihe Medical Technology Co., Ltd. (hereinafter referred to as Huihe Medical) announced the completion of its Series D financing round. This round was strategically led by China Taiping Healthcare Fund, with follow-on investment from its existing shareholder Sherpa Healthcare Fund II (Suzhou) Equity Investment Partnership (Limited Partnership) (hereinafter referred to as Sherpa). This marks another important milestone for Huihe Medical following the closing of its Series C+ financing in 2022, and attests to the capital market’s high recognition of the company’s innovative strength in the field of interventional therapy for structural heart disease. Picture：From VB100 In recent years, insurance capital has emerged as a vital driving force for the development of the healthcare industry. As a quintessential representative of patient capital, insurance capital boasts distinctive strengths in long-term sustainability, stability and cross-cycle asset allocation, which are highly aligned with the healthcare industry’s inherent traits of long investment cycles ...
- Source: drugdu
- 75
- December 30, 2025
FDA Approved! Novel Anti-Cancer Bispecific Antibody to Initiate Phase I Clinical Trial

On December 29, Celltrion announced that its bispecific antibody drug CT-P72/ABP-102, co-developed with US-based Abpro Corporation for the treatment of HER2-positive solid tumors, has obtained approval from the U.S. Food and Drug Administration (FDA) and is set to initiate a Phase I clinical trial. ABP-102 is a bispecific T-cell engager (BiTE) targeting HER2 and CD3, engineered with a tetravalent IgG1-[L]-single-chain variable fragment (scFv) format. This molecule is designed to selectively eliminate tumor cells with high HER2 expression, and by reducing the affinity of its HER2-binding arm, it effectively mitigates off-target toxicities to normal tissues with low HER2 expression. In a corporate statement, Celltrion noted that it plans to start administering the drug to patients in the next year upon completion of relevant preparatory work. Preclinical research data presented at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in November demonstrated that the drug inhibited tumor growth in ...
- Source: drugdu
- 71
- December 30, 2025
Transcenta Group-B and EirGenix Reach Biopharmaceutical Manufacturing Collaboration Agreement

On December 29, Transcenta Holdings Group-B (06628) announced a strategic collaboration and non-exclusive technology licensing agreement with EirGenix. The agreement aims to advance integrated continuous flow manufacturing of biopharmaceuticals and improve global accessibility to affordable biopharmaceuticals. Under the agreement, the company will grant EirGenix a non-exclusive license to its highly integrated continuous flow bioprocess manufacturing (HiCB) platform and provide complete process documentation, core process technologies and experience, and regulatory support services. The company will receive a substantial upfront payment and milestone payments, and will be able to collect future royalties related to the commercialization of the licensed technology. This collaboration is expected to significantly reduce production costs, enabling patients worldwide to access high-quality, affordable biologics. EirGenix plans to use the HiCB platform for its biologics development programs and manufacturing operations, supporting CDMO customers seeking highly integrated continuous flow manufacturing solutions. https://finance.eastmoney.com/a/202512293604195792.html
- Source: drugdu
- 59
- December 30, 2025
China’s first imported PD-L1 subcutaneous formulation approved! Atezolizumab subcutaneous formulation receives NMPA approval for market launch

Atezolizumab is a monoclonal antibody targeting PD-L1. This approval of the subcutaneous (SC) formulation of atezolizumab is based on positive results from the IMscin001 study. IMscin001 was a two-part dose-exploration (Phase Ib) and confirmatory (Phase III) study designed to evaluate the pharmacokinetics of subcutaneous (SC) administration of atezolizumab compared to intravenous (IV) administration in patients with locally advanced or recurrent metastatic non-small cell lung cancer (NSCLC). Clinical endpoints included objective response rate (ORR), progression-free survival (PFS) or overall survival (OS), serious adverse events, adverse events of particular concern, grade 3–5 adverse events, infusion-related reactions, and injection site reactions related to safety. The results showed [1] that the C trough and AUC 0-21 d of atezolizumab SC were consistent with those of atezolizumab IV. The PFS [hazard ratio (HR) 1.08 (95% CI [0.82-1.41]], ORR (SC: 12% vs. IV: 10%), and incidence of adverse events (SC: 19.5% vs. IV: 13.9%) were similar ...
- Source: drugdu
- 66
- December 30, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.